News

By creating customized packages that incorporate the range of diagnostic and treatment options available, practices can simplify dry eye management and improve patients' outcomes.

A team of investigators has found that myopic refractive error is linked with an increased risk of primary open-angle glaucoma, and they indicate that the connection has a genetic foundation.

Physician offers "real talk" on pros and cons that offers surgeons and patients decision-making insights.

Currently enrolling a Phase 2 trial to evaluate the role of complement factor B protein in age-related macular degeneration (AMD)

Low-grade inflammation seems to be associated with baseline disease in inherited retinal dystrophies (IRDs), according to Christine N. Kay, MD, a surgeon at Vitreoretinal Associates, in Gainesville, Florida.

APOE4 gene associated with Alzheimer’s disease risk was found to protect mice from glaucoma. Research team also prevented retinal ganglion cell death by blocking the APOE signaling pathway, pointing to a potential treatment strategy for glaucoma.

The investigators retrospectively analyzed treatment-naive eyes with DME which received intravitreal treatment with either ranibizumab 0.5 mg or aflibercept 2 mg. All data were collected in the Fight Retinal Blindness! registry.

X-linked retinoschisis is a congenital disorder that results in visual impairment in boys at an early age. No treatment is currently available, and surgical repair fails in many cases.

Foundation Fighting Blindness is a driving force in advancing retinal gene therapies into clinical trials.

A team of investigators has found that myopic refractive error is linked with an increased risk of primary open-angle glaucoma, and they indicate that the connection has a genetic foundation.

Moving past the eyes and into the brain: It is vital to think beyond the eye in the presence of visual impairment and blindness.

According to the company, a study shows the non-implantable minimally invasive glaucoma surgery effectively reduces IOP and reduces need for IOP-lowering medications in patients diagnosed with open-angle glaucoma.

This discovery provides potential for treatment strategy to prevent blindness from glaucoma.

An independent data monitoring committee recommends continuing study with a sample size target of up to 350 Patients. According to the company, no safety concerns have been identified and topline results are expected during the second quarter of 2023.

According to Johns Hopkins Medicine researchers, as little as $65 per year appears to influence practitioners, making them up to twice as likely to prescribe the companies’ brand name eyedrops for glaucoma instead of cheaper generic versions.

Zonular crises occur due to many different aetiologies, but ophthalmologists now have multiple tools available to solve complex problems and achieve excellent results in complex cases.

Researchers at Linköping University have used implants made from pig skin to restore sight to 20 people with diseased corneas.

With the support of Harrington Discovery Institute at University Hospitals, an ophthalmic therapeutic dubbed KIO-301, initially developed by Richard Kramer, PhD, at the University of California, Berkeley (UCB), has successfully been granted approval to start a Phase 1b, first-in-human clinical trial.

CAM encourages corneal healing in patients with ocular surface disease.

Combined, the companies say they will create the largest eye bank, tissue recovery and ocular research center in the world.

Researchers at the Medical University of Vienna are focusing on how the retina can be used as a prognostic marker. Analyses revealed that retinal layer thinning as a result of an MS relapse predicts the severity of future relapses and the likelihood of disability.

In a study, investigators found that no characteristics of inflammatory bowel disease are related to ocular manifestations of the disease.

The U.S. Food and Drug Administration has approved Coherus’ ranibizumab-eqrn (Cimerli) as an interchangeable biosimilar for all five indications of Lucentis.

Donald Salzberg, MD, conspired with an alleged accomplice at a medical diagnostic company in a scheme that ran for five years, from 2014 through 2019, according to U.S. attorney’s office in Boston.

The companies note that data from Study CPN-302 confirm the results in the first Phase 3 study, CPN-301, and they demonstrate the clear benefits of treating patients after cataract surgery with APP13007.

The study provided evidence of safety, visual acuity improvement and structural stability in a difficult-to-treat patient population.

Anika Michael, MD, and Benjeil Edghill, MD, both ophthalmology specialists from AdvantageCare Physicians New York City, traveled to Haiti in July on a medical mission of mercy, where they evaluated and treated more than 400 patients and completed approximately 90 surgeries.

This year’s hybrid meeting will allow attendees to participate in person or virtually. Either way, this congress will offer a wealth of information to specialists covering all aspects of retinal diseases.